基于共有峰率和变异峰率双指标序列分析法的芡实红外指纹图谱研究

目的:建立不同产地芡实的红外指纹图谱。方法:利用共有峰率和变异峰率2个指标,以不同产地芡实的红外指纹图谱为标准,计算出17个样品间的共有峰率和变异峰率,按照其大小建立了不同的共有峰率和变异峰率双指标序列分析法,研究各产地芡实的异同。结果:产地相近的S13与S12、S14之间,S2与S3之间有很高的共有峰率(均不低于82.4%)和很低的变异峰率(均不超过21.4%);产地不同但品种一致的S9与S1、S15之间,S4与S6之间有不高的共有峰率(均不超过52.4%)和不低的变异峰率(均不低于33.3%);地理位置相距较远的S16与S8、S6之间,S17与S4、S8之间有较低的共有峰率(均不超过47.6%)和较高的变异峰率(均不低于50.0%);产地不同且采收期较近,造成了S10与其他产地样品相比有着极低的共有峰率(均不超过35.7%)和极高的变异峰率(几乎均高于100%)。结论:双指标序列分析法结合红外指纹图谱能够指导判别不同产地的芡实,简便、快捷,可为芡实等水生植物药材的质量评价提供一种新方法。     

Recognizing the advantage of employing the PowerPlex® ESI and PowerPlex® ESX complementary kits for purposes of clarification in routine casework

In an effort to promote European cross-border cooperation in fighting crime and international terrorism the Treaty of Prüm was drafted and accepted within the European forensic community. This move led to the commercial development of new multiplex kits which introduced five new STR loci and promised better performance. Recently the Israel Police DNA Casework and Database laboratories adopted the PowerPlex^® ESI kit for routine use in our laboratories. Presented in this paper are examples of three types of ambiguous results encountered during the implementation of the PowerPlex^® ESI kit into routine work. These ambiguous products presented themselves in the form of (1) extreme variants outside of loci borders, (2) failure to amplify sister allele pairs or expression of null alleles and (3) episodes of loss of separation of adjacent microvariants primarily in mixture samples. The re-analysis of all these samples using the PowerPlex^® ESX kit successfully and rapidly clarified all three categories of anomalies.Spotlighting such events to the forensic community, especially regarding the novel loci introduced in these next generation kits, can aid in raising the analyst's awareness to their future appearances and prevent possible erroneous conclusions. In addition, providing timely DNA results to investigating teams is of great importance and operational forensic laboratories do not have at their immediate disposal methods such as sequencing to elucidate such manifestations. We suggest that the complementary use of the PowerPlex^® ESI and PowerPlex^® ESX can provide a benefit for clarification purposes in routine casework.     

高压氧对异体骨植骨愈合的疗效评价

目的研究高压氧治疗对异体骨植骨术后骨愈合的临床价值。方法将99例骨肿瘤进行异体骨植骨手术的患者分成2组，高压氧组41例，采用异体骨植骨＋高压氧治疗；对照组58例，采用单纯异体骨植骨。观察2组术后切口的炎症反应、肿胀消退时间、引流量，并利用X线片观察骨折线模糊时间、消失时间及骨密度变化情况。结果平均随访20个月，高压氧组切口的炎症反应明显减轻，肿胀消退时间减少了2d，引流量减少约28％，骨折愈合提前了约3个月，两组结果比较差异有统计学意义（P〈0．01）。结论高压氧治疗可以明显地减轻异体骨植骨术后组织的炎症反应，减少出血及感染，促进了骨愈合，减少了术后并发症的发生，有较好的应用前景。     

一起由新甲1型流感病毒变种引起的流感爆发

本文报告1986年4月成都某大学的一起流感爆发,学生中罹患率高达28％,流行高峰在4天以内。从32份急性期流感病人咽漱液标本中共分离出三株病毒。经病毒学鉴定和患者双份血清的血清学试验证实,此新分离的三株病毒均属新甲1型流感病毒的变种,其抗原性与我国北方正在流行的A1/青防85-42相似。提示新甲1型流感病毒的变种在我国已由北向南传播。     

中药配方颗粒宣肺脱敏方治疗咳嗽变异性哮喘(CVA)60例临床疗效观察

目的:探讨宣肺脱敏方治疗咳嗽变异性哮喘(CVA)临床疗效。方法:选取我院收治的60例咳嗽变异性哮喘患者为研究对象,随机分为治疗组和对照组,对照组30例采用吲哚美辛肠溶片和马来酸氯苯那敏片治疗,治疗组30例采用宣肺脱敏方治疗,统计3 d缓解率。结果:两组患者治疗3 d后,治疗组缓解率高达93.3%,对照组为76.7%,两组对比差异显著(P0.05),具有统计学意义。结论:宣肺脱敏方治疗咳嗽变异性哮喘起效快,效果确切,可以大力推广应用。     

Review of the early reports of the epidemiological characteristics of the B.1.1.7 variant of SARS-CoV-2 and its spread worldwide

The variant B.1.1.7 of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the RNA virus causing the pandemic more than a year worldwide, was reported from United Kingdom (UK) in late December 2020. It was reported that mortality increases by 65% and transmissibility increases by 70%, which may result in an increase of reproduction number to 1.13-1.55 from 0.75-0.85. To analyze the global increasing trend of the variant B.1.1.7, we extracted results of B.1.1.7 from GISAID on May 11 and May 12, 2021, and conducted a dose-response regression. It took 47 days to reach 20% and 121 days to reach 50% among the sequence submitted from UK. In Korea, cases of B.1.1.7 have increased since the first report of three cases on December 28, 2020. Positive rate of B.1.1.7 in Korea was 21.6% in the week from May 9 to May 15, 2021. Detection rate of the variants is expected to increase further and new variants of SARS-CoV-2 are emerging, so a close monitoring and control would be maintained for months.